BTMD - NASDAQ
biote Corp.
$2.11
+5.5%biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.
At a Glance
Live Snapshotbiote Corp. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Net Profit Margin
Strong net margins indicate efficient operations and favorable tax/interest management.
Effective Tax Rate
Moderate tax rate typical for most corporations. Represents standard tax burden on profits.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
biote Corp. Income Statement
BTMD • NASDAQ
| biote Corp. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
192.2M | 197.2M | 185.4M | 165M | 139.4M | 116.6M | 110M | |
GROSS PROFIT | |||||||
(54.9M) | (58.1M) | (57.9M) | (54.6M) | (48.8M) | (44.9M) | (43.6M) | |
137.4M | 139.1M | 127.5M | 110.4M | 90.6M | 71.6M | 66.4M | |
OPERATING INCOME | |||||||
(101.8M) | (107.5M) | (98.8M) | (171.1M) | (56M) | (39.9M) | (42.9M) | |
(101.8M) | (107.5M) | (0.0) | (171.1M) | (54M) | (37.4M) | (39.3M) | |
35.6M | 31.6M | 28.7M | -60.7M | 34.6M | 31.8M | 23.5M | |
PRE-TAX INCOME | |||||||
(11M) | (11M) | (6.4M) | (4M) | (1.7M) | (2.4M) | (2.1M) | |
-11M | -11M | -6.4M | -4M | -1.7M | -2.4M | -2.1M | |
(0.0) | (0.0) | (98.8M) | (0.0) | (2.1M) | (2.4M) | (3.6M) | |
2M | -30.6M | -28.8M | 62.4M | -1.7M | -2.4M | -2.1M | |
37.6M | 1M | -123K | 1.7M | 32.9M | 29.4M | 21.4M | |
NET INCOME | |||||||
(6M) | (970K) | (2.7M) | (388K) | (286K) | (189K) | (93K) | |
27M | 3.2M | 3.3M | -969K | 32.6M | 29.2M | 21.3M |
SEC Filings
BTMD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | May 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 18, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 02, 2026 | May 12, 2026 | 2026 |
Related Guides
Continue your BTMD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.